Mr. Scaffa has over 30 years of relevant experience with large pharmaceutical companies, most recently with Zoetis Inc. He will be responsible for establishing robust quality systems for the Company’s Nisin-based treatment for subclinical mastitis in lactating dairy cows.
“Gustavo brings a depth of experience to our team as we progress through the final stages of our New Animal Drug Application with the FDA,” commented Michael F. Brigham, President and CEO. “We are excited to have him relocate to Maine and join us.”
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef livestock. The Company is developing a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at: http://www.immucell.com.